<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pseudomonas aeruginosa pneumonia</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pseudomonas aeruginosa pneumonia</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pseudomonas aeruginosa pneumonia</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Souha S Kanj, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Stephen B Calderwood, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Keri K Hall, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 08, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span><em>Pseudomonas aeruginosa</em> is one of the most important and most commonly considered pathogens in the differential diagnosis of gram-negative infections. Consideration of this organism is important because it causes severe hospital-acquired infections, especially in immunocompromised hosts, is often antibiotic resistant, complicating the choice of therapy, and is associated with a high mortality rate.</p><p>The clinical manifestations, diagnosis, and treatment of <em>P. aeruginosa</em> pneumonia will be reviewed here. </p><p>The general principles of antimicrobial treatment of infections caused by <em>P. aeruginosa</em>, including antibiotic options and decisions on combination therapy, are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3135.html" rel="external">"Principles of antimicrobial therapy of Pseudomonas aeruginosa infections"</a>.)</p><p>The clinical manifestations and management of other <em>P. aeruginosa</em> infections and the epidemiology and pathogenesis of infection with this organism are also discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3142.html" rel="external">"Epidemiology, microbiology, and pathogenesis of Pseudomonas aeruginosa infection"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2136.html" rel="external">"Pseudomonas aeruginosa bacteremia and endocarditis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7643.html" rel="external">"Pseudomonas aeruginosa skin and soft tissue infections"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3148.html" rel="external">"Pseudomonas aeruginosa infections of the eye, ear, urinary tract, gastrointestinal tract, and central nervous system"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6371.html" rel="external">"Cystic fibrosis: Antibiotic therapy for chronic pulmonary infection", section on 'Pseudomonas aeruginosa'</a> and  <a class="medical medical_review" href="/z/d/html/140721.html" rel="external">"Cystic fibrosis: Antibiotic therapy for pulmonary exacerbations"</a>.) </p><p></p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span></p><p class="headingAnchor" id="H3"><span class="h2">Hospital-acquired pneumonia</span><span class="headingEndMark"> — </span><em>P. aeruginosa</em> is a common cause of gram-negative hospital-acquired (nosocomial) pneumonia [<a href="#rid1">1-6</a>]. This was illustrated in a prospective series of 556 patients in which <em>P. aeruginosa</em> was the most common gram-negative pathogen implicated in both hospital-acquired and ventilator-associated pneumonia (VAP) [<a href="#rid1">1</a>]. In a large multicenter survey of gram-negative aerobic bacteria isolated from patients in intensive care units (ICUs) in the US, <em>P. aeruginosa</em> was the most commonly isolated gram-negative aerobic bacterium (23 percent) and was the most common bacterium recurrently isolated from the respiratory tract (32 percent) [<a href="#rid7">7</a>]. Hospital-acquired pneumonia (HAP) can occur via aspiration of endogenous oral flora or via aspiration of organisms from contamination of ventilator tubing or other health care devices [<a href="#rid8">8,9</a>]. Pulmonary infections due to <em>P. aeruginosa</em> may also arise hematogenously [<a href="#rid10">10</a>]. <em>P. aeruginosa</em> is also an important cause of nosocomial tracheobronchitis [<a href="#rid2">2</a>]. (See  <a class="medical medical_review" href="/z/d/html/7020.html" rel="external">"Epidemiology, pathogenesis, microbiology, and diagnosis of hospital-acquired and ventilator-associated pneumonia in adults"</a>.)</p><p>Several risk factors for HAP due to <em>P. aeruginosa</em> have been identified. In one study, a higher probability of <em>P. aeruginosa</em> pneumonia was associated with increased age, length of mechanical ventilation, antibiotics at admission, transfer from a medical unit or ICU, and admission in a ward with higher incidence of patients with <em>P. aeruginosa</em> infections [<a href="#rid11">11</a>]. A lower probability of <em>P. aeruginosa</em> was associated with trauma and admission in a ward with high patient turnover.</p><p><em>P. aeruginosa</em> is a common cause of secondary bacterial pneumonia in individuals hospitalized with COVID-19. (See  <a class="medical medical_review" href="/z/d/html/3142.html" rel="external">"Epidemiology, microbiology, and pathogenesis of Pseudomonas aeruginosa infection", section on 'Secondary infections in patients with COVID-19'</a>.) </p><p class="headingAnchor" id="H5"><span class="h2">Community-acquired pneumonia</span><span class="headingEndMark"> — </span>In general, community-acquired <em>P. aeruginosa</em> pneumonia is a rare occurrence. While its exact incidence is unknown, multi-national studies show its prevalence to be around 4 percent [<a href="#rid12">12</a>]. Community-acquired <em>P. aeruginosa</em> pneumonia is occasionally reported in otherwise healthy hosts [<a href="#rid13">13</a>]. In a recent review of the literature on immunocompetent individuals who did develop community-acquired <em>P. aeruginosa</em>, identified risk factors were [<a href="#rid14">14</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>Advanced age</p><p class="bulletIndent1"><span class="glyph">●</span>Smoking</p><p class="bulletIndent1"><span class="glyph">●</span>Alcohol use</p><p class="bulletIndent1"><span class="glyph">●</span>Exposure to contaminated liquids</p><p></p><p>Most patients have an identifiable risk factor for disease. Community-acquired <em>P. aeruginosa</em> pneumonia occurs mainly in individuals who have [<a href="#rid12">12,15-17</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>A compromised immune system (eg, patients with HIV, solid organ or hematopoietic cell transplant recipients, neutropenic hosts, and those on immunosuppressive or immunomodulatory agents such as TNF-alfa inhibitors)</p><p class="bulletIndent1"><span class="glyph">●</span>Recent prior antibiotic use</p><p class="bulletIndent1"><span class="glyph">●</span>Structural lung abnormalities such as cystic fibrosis or bronchiectasis</p><p class="bulletIndent1"><span class="glyph">●</span>Repeated exacerbations of chronic obstructive pulmonary disease requiring frequent glucocorticoid and/or antibiotic use</p><p></p><p>As an example, <em>P. aeruginosa</em> causes 5 to 7 percent of cases of community-acquired pneumonia in patients with HIV [<a href="#rid18">18,19</a>]. In another retrospective study of over 10,000 patients hospitalized for pneumonia, <em>P. aeruginosa</em> was most highly associated with bronchiectasis (adjusted odds ratio [aOR] = 6.13), lung abscess/empyema (aOR = 3.36), and chronic obstructive pulmonary disease (COPD; aOR = 1.84), although the rate of <em>P. aeruginosa</em> in patients with COPD but no other comorbidities was similar to the rate in the general population [<a href="#rid20">20</a>]. Additional risk factors for community-acquired pneumonia due to <em>P. aeruginosa</em> include cirrhosis [<a href="#rid21">21</a>], history of recent hospitalization [<a href="#rid16">16</a>], intubation [<a href="#rid22">22</a>], or enteral tube feeding [<a href="#rid23">23</a>]. In one study, <em>P. aeruginosa</em> pneumonia was responsible for 39 out of 559 cases of community-acquired pneumonia; previous hospital admission and pulmonary comorbidity were predictive of the occurrence of this infection [<a href="#rid16">16</a>].</p><p>Person-to-person transmission of <em>P. aeruginosa</em> in the community is rare, but has been reported in a few isolated instances. As an example, household spread was documented when a daughter passed a <em>P. aeruginosa</em> strain to her mother, causing cavitary pneumonia and lung abscess; the two isolates were confirmed to be identical using pulsed-field gel electrophoresis [<a href="#rid24">24</a>].</p><p>Other rare risks for <em>P. aeruginosa</em> include environmental exposures. As an example, one report described an isolated case of necrotizing <em>P. aeruginosa</em> pneumonia in an immunocompetent patient that was attributed to contact with a contaminated hot tub filter. This case highlights the importance of following the United States Centers for Disease Control and Prevention (CDC) guidelines for hot tub maintenance to prevent <em>Pseudomonas</em> overgrowth [<a href="#rid25">25</a>].</p><p class="headingAnchor" id="H1410424"><span class="h2">Equipment-related outbreaks</span><span class="headingEndMark"> — </span>Outbreaks of <em>P. aeruginosa</em> infection linked to contaminated health care equipment such as endoscopes have been occasionally reported [<a href="#rid26">26-28</a>].</p><p>Bronchoscope contamination has been linked to defective design, bronchoscope damage, and inadequate disinfection [<a href="#rid29">29</a>]. One outbreak related to defective bronchoscopes led to 32 cases of <em>P. aeruginosa</em> infections and three deaths prior to a voluntary recall of the endoscopes by the manufacturer [<a href="#rid27">27</a>].</p><p class="headingAnchor" id="H6"><span class="h1">CLINICAL FEATURES</span></p><p class="headingAnchor" id="H1410603"><span class="h2">Signs and symptoms</span><span class="headingEndMark"> — </span>Signs and symptoms of pneumonia caused by <em>P. aeruginosa</em> are similar to those caused by other pyogenic bacteria and <em>Legionella</em>. No features can reliably distinguish infection with <em>P. aeruginosa</em> from pneumonia caused by those other pathogens. Acute <em>P. aeruginosa</em> pneumonia is usually characterized by cough productive of purulent sputum, dyspnea, fever, chills, confusion, and severe systemic toxicity. Patients with ventilator-associated <em>P. aeruginosa</em> pneumonia may also present with increased tracheobronchial secretions and decreased ventilator performance that can develop suddenly or gradually.</p><p>Although <em>P. aeruginosa</em> is typically associated with severe pneumonia, this is not a distinguishing feature. In a study of 343 patients with hospital-acquired pneumonia, the severity of illness was not associated with or predictive of microbial etiology [<a href="#rid30">30</a>].</p><p>The general clinical features of community- and hospital-acquired pneumonia (HAP) are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7032.html" rel="external">"Clinical evaluation and diagnostic testing for community-acquired pneumonia in adults", section on 'Clinical evaluation'</a> and  <a class="medical medical_review" href="/z/d/html/7020.html" rel="external">"Epidemiology, pathogenesis, microbiology, and diagnosis of hospital-acquired and ventilator-associated pneumonia in adults", section on 'Diagnosis'</a> and  <a class="medical medical_review" href="/z/d/html/1635.html" rel="external">"Clinical presentation and diagnostic evaluation of ventilator-associated pneumonia"</a>.)</p><p class="headingAnchor" id="H7"><span class="h2">Radiology</span><span class="headingEndMark"> — </span>Radiographic findings are variable and no single finding is predictive or characteristic of <em>P. aeruginosa</em> pneumonia. Diffuse bilateral infiltrates, with or without pleural effusion, may be present. Many patients have multifocal airspace consolidation. Other radiographic features include nodular infiltrates, tree-in-bud opacities, and necrosis [<a href="#rid31">31</a>]. Occasionally, areas of radiolucency suggestive of cavitary disease may be present. Classic lobar consolidation is uncommon.</p><p>When <em>P. aeruginosa</em> pneumonia arises from hematogenous spread of the organism, early radiographic findings may include pulmonary congestion and interstitial edema. However, diffuse interstitial and alveolar infiltrates often develop 24 to 48 hours later in such patients. Large hemorrhagic nodules with central necrosis or cavities may rarely occur later in the course.</p><p>Radiographic findings in certain hosts may also have particular characteristics. As an example, in a small study of 16 HIV-infected patients with <em>P. aeruginosa</em> pneumonia, of whom the majority had low CD4 cell counts, 11 presented with or subsequently developed cavitary infiltrates [<a href="#rid32">32</a>].</p><p class="headingAnchor" id="H8"><span class="h2">Pathology</span><span class="headingEndMark"> — </span>Histopathologic changes in patients with pneumonia due to <em>P. aeruginosa</em> typically include microabscesses with focal hemorrhage and necrosis of the alveolar septae without evidence of bacterial invasion of vessel walls or vascular necrosis. Pathologic changes in patients with pneumonia due to hematogenous spread usually include intra-alveolar hemorrhage and necrosis around pulmonary vessels. Small (2 to 15 mm), firm, yellow-brown necrotic nodules with dark red hemorrhagic parenchyma may also be present along with liquefactive necrosis or bacterial invasion of the alveolar cell walls.</p><p>One autopsy study of eight infants with <em>P. aeruginosa</em> pneumonia revealed two distinct histopathological patterns. Seven cases demonstrated evidence of a distinctive paucicellular coagulative confluent bronchopneumonia with perivascular bacillary infiltration. These changes occurred in immunocompromised patients with sepsis and rapid deterioration. The eighth case, a patient with an unusually protracted clinical course, had pathologic changes typical of bacterial pneumonia without evidence of perivascular organisms [<a href="#rid33">33</a>].</p><p class="headingAnchor" id="H1410697"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of <em>P. aeruginosa</em> pneumonia is made following the growth of <em>P. aeruginosa</em> on culture of expectorated sputum, bronchoscopically obtained samples, or other respiratory specimens in a patient with clinical and radiographic findings consistent with pneumonia. The diagnostic evaluation for pneumonia is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7032.html" rel="external">"Clinical evaluation and diagnostic testing for community-acquired pneumonia in adults"</a> and  <a class="medical medical_review" href="/z/d/html/7020.html" rel="external">"Epidemiology, pathogenesis, microbiology, and diagnosis of hospital-acquired and ventilator-associated pneumonia in adults", section on 'Diagnosis'</a> and  <a class="medical medical_review" href="/z/d/html/1635.html" rel="external">"Clinical presentation and diagnostic evaluation of ventilator-associated pneumonia", section on 'Diagnostic evaluation'</a>.)</p><p>In some cases, particularly in the settings of intubation or chronic bronchiectasis, which can be associated with chronic growth of <em>P. aeruginosa</em> in the airways, the distinction between respiratory infection and colonization with <em>P. aeruginosa</em> may be difficult to make. Changes in clinical status such as new fever, new leukocytosis, new abnormality on chest imaging, and worsened respiratory status are suggestive of pneumonia in patients chronically colonized with <em>P. aeruginosa</em>. The use of quantitative cultures on sputum specimens from ventilated patients may also be helpful in distinguishing between infection and colonization [<a href="#rid34">34</a>], but these techniques are not widely available and their use in clinical practice is uncommon. (See  <a class="medical medical_review" href="/z/d/html/1635.html" rel="external">"Clinical presentation and diagnostic evaluation of ventilator-associated pneumonia", section on 'Diagnostic evaluation'</a>.)</p><p class="headingAnchor" id="H9"><span class="h1">MANAGEMENT</span></p><p class="headingAnchor" id="H1410895"><span class="h2">Empiric antimicrobial therapy</span><span class="headingEndMark"> — </span>Until antimicrobial susceptibility results are available, we initially treat known or suspected cases of <em>P. aeruginosa</em> pneumonia with a single antimicrobial agent, unless the patient has sepsis or risk factors for a drug resistant infection, in which case we use two antibiotics from different classes to which the isolate is likely to be susceptible  (<a class="graphic graphic_table graphicRef91115" href="/z/d/graphic/91115.html" rel="external">table 1</a>).</p><p>Specifically, we agree with the guidelines from the Infectious Diseases Society of America and the American Thoracic Society on the empiric management of community-acquired and hospital-acquired pneumonia (HAP) that recommend the following antimicrobial combinations for patients who have risk factors for both <em>P. aeruginosa</em> infection as well as drug resistance [<a href="#rid15">15,35</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>An antipseudomonal beta-lactam PLUS an antipseudomonal quinolone</p><p class="bulletIndent1"><span class="glyph">●</span>An antipseudomonal beta-lactam PLUS an aminoglycoside</p><p class="bulletIndent1"><span class="glyph">●</span>An antipseudomonal quinolone PLUS an aminoglycoside</p><p></p><p>Antipseudomonal beta-lactams include <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">piperacillin-tazobactam</a>, <a class="drug drug_general" data-topicid="9226" href="/z/d/drug information/9226.html" rel="external">ceftazidime</a>, <a class="drug drug_general" data-topicid="9215" href="/z/d/drug information/9215.html" rel="external">cefepime</a>, <a class="drug drug_general" data-topicid="8553" href="/z/d/drug information/8553.html" rel="external">imipenem</a>, and <a class="drug drug_general" data-topicid="9613" href="/z/d/drug information/9613.html" rel="external">meropenem</a>. <a class="drug drug_general" data-topicid="9047" href="/z/d/drug information/9047.html" rel="external">Aztreonam</a> may be substituted for one of these in the setting of penicillin allergy. Antipseudomonal quinolones include <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">ciprofloxacin</a> and <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">levofloxacin</a> (750 mg dose).</p><p>Antimicrobial selection should also include consideration of local epidemiology and local antimicrobial resistance patterns, particularly in patients at risk for multidrug-resistant <em>P. aeruginosa</em>. In settings where multidrug resistance is common, novel expanded-spectrum beta-lactam agents (such as <a class="drug drug_general" data-topicid="98763" href="/z/d/drug information/98763.html" rel="external">ceftolozane-tazobactam</a>) may be appropriate for empiric therapy [<a href="#rid36">36-44</a>]. Additional details, including dosing, on antibiotic regimens for the treatment of <em>P. aeruginosa</em> infections are found in the table  (<a class="graphic graphic_table graphicRef91115" href="/z/d/graphic/91115.html" rel="external">table 1</a>) and are elaborated on elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3135.html" rel="external">"Principles of antimicrobial therapy of Pseudomonas aeruginosa infections", section on 'Intravenous antibiotics'</a>.)</p><p>Risk factors for <em>P. aeruginosa</em> among patients presenting with hospital- or community-acquired pneumonia are discussed elsewhere, as are risk factors for antimicrobial resistance. (See <a class="local">'Epidemiology'</a> above and  <a class="medical medical_review" href="/z/d/html/3135.html" rel="external">"Principles of antimicrobial therapy of Pseudomonas aeruginosa infections", section on 'Antimicrobial resistance'</a>.)</p><p>The evidence for combination versus monotherapy is also discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3135.html" rel="external">"Principles of antimicrobial therapy of Pseudomonas aeruginosa infections", section on 'Role of combination antimicrobial therapy'</a>.)</p><p class="headingAnchor" id="H11"><span class="h2">Directed antimicrobial therapy</span></p><p class="headingAnchor" id="H1410985"><span class="h3">Regimen choice</span><span class="headingEndMark"> — </span>We suggest streamlining empiric combination therapy to a single active antibiotic once susceptibility results are available  (<a class="graphic graphic_table graphicRef91115" href="/z/d/graphic/91115.html" rel="external">table 1</a>). We typically use a beta-lactam, reserving carbapenems for treating polymicrobial infections or organisms resistant to other agents. Advanced beta-lactams, such as <a class="drug drug_general" data-topicid="98763" href="/z/d/drug information/98763.html" rel="external">ceftolozane-tazobactam</a>, <a class="drug drug_general" data-topicid="100152" href="/z/d/drug information/100152.html" rel="external">ceftazidime-avibactam</a>, and <a class="drug drug_general" data-topicid="121885" href="/z/d/drug information/121885.html" rel="external">imipenem-cilastatin-relebactam</a>, can be used as monotherapy, if active, for isolates of <em>P. aeruginosa</em> that are resistant to the traditional antipseudomonal drugs [<a href="#rid45">45</a>]. In general, aminoglycosides should <strong>not</strong> be used as monotherapy for pneumonia because they perform poorly in an acidic environment.</p><p><a class="drug drug_general" data-topicid="98763" href="/z/d/drug information/98763.html" rel="external">Ceftolozane-tazobactam</a>'s efficacy in treating nosocomial pneumonia has been demonstrated in the ASPECT-NP trial where it proved to be noninferior to <a class="drug drug_general" data-topicid="9613" href="/z/d/drug information/9613.html" rel="external">meropenem</a> in terms of 28-day mortality [<a href="#rid37">37</a>]. In addition, the supplementary analysis to the ASPECT-NP trial showed that ceftolozane-tazobactam prevented the emergence of resistance in <em>P. aeruginosa</em> as opposed to the meropenem group, where 22.4 percent of the isolates became resistant [<a href="#rid46">46</a>].Furthermore, its ability to enable shorter ICU stays and duration of mechanical ventilation was demonstrated in separate studies [<a href="#rid47">47</a>]. Ceftolozane-tazobactam has also proven superiority in terms of mortality with less risk of adverse effects when compared to polymyxin or aminoglycoside-based regimens [<a href="#rid48">48-50</a>].</p><p>Real-world data have consistently shown <a class="drug drug_general" data-topicid="98763" href="/z/d/drug information/98763.html" rel="external">ceftolozane-tazobactam</a>'s effectiveness and safety [<a href="#rid43">43,51-53</a>].</p><p>In a multi-center, retrospective analysis of 206 patients with HAP/ventilator-associated pneumonia (VAP) secondary to MDR or extensively drug-resistant (XDR) <em>P. aeruginosa</em> where <a class="drug drug_general" data-topicid="98763" href="/z/d/drug information/98763.html" rel="external">ceftolozane-tazobactam</a> was compared to the best available therapy, treatment with ceftolozane-tazobactam was independently associated with a 73.3 percent reduction in clinical failure, compared to those who received best available therapy, along with a lower rate of adverse events (10 versus 33 percent). Nephrotoxicity (85 percent) and <em>Clostridioides difficle</em> infection (5 percent) were the most commonly side effects [<a href="#rid52">52</a>]. In another multicenter study in which ceftolozane-tazobactam was used as outpatient therapy, where 18 percent of infections were respiratory infections and 23 percent were secondary to <em>P. aeruginosa</em>, 95 percent of infections clinically resolved [<a href="#rid53">53</a>].</p><p><a class="drug drug_general" data-topicid="100152" href="/z/d/drug information/100152.html" rel="external">Ceftazidime-avibactam</a> has also proven its efficacy in treating nosocomial pneumonia in the REPROVE trial where it was found to be noninferior to <a class="drug drug_general" data-topicid="9613" href="/z/d/drug information/9613.html" rel="external">meropenem</a> [<a href="#rid54">54</a>].</p><p>Real-world data published so far for the treatment of HAP/VAP confirmed the high efficacy and tolerability of this novel beta-lactam beta-lactamase inhibitor (BL-BLI) [<a href="#rid55">55-58</a>]. In the largest cohort to date, <a class="drug drug_general" data-topicid="100152" href="/z/d/drug information/100152.html" rel="external">ceftazidime-avibactam</a> was assessed for severe pulmonary infections due to carbapenem-resistant and difficult-to-treat <em>P. aeruginosa</em>;<em> </em>63 percent achieved clinical cure with bacterial eradication in 80 percent of the cases and an all-cause mortality of 19 percent by day 30 [<a href="#rid57">57</a>].</p><p>There are only a few studies that compared <a class="drug drug_general" data-topicid="98763" href="/z/d/drug information/98763.html" rel="external">ceftolozane-tazobactam</a> to <a class="drug drug_general" data-topicid="100152" href="/z/d/drug information/100152.html" rel="external">ceftazidime-avibactam</a>. A recent multi-center retrospective cohort study compared both of these BL-BLIs in treating <em>P. aeruginosa</em> infections and looked at overall in-hospital mortality, 30-day mortality, and clinical cure, 28 percent of which were diagnosed with HAP and 21 percent with VAP. The three outcomes were comparable in both groups. In addition, no difference was found in other outcomes, including infection-related mortality, 30-day readmission, 30-day recurrence, 90-day recurrence, microbiologic eradication, length of stay, or duration of mechanical ventilation [<a href="#rid59">59</a>].</p><p><a class="drug drug_general" data-topicid="121885" href="/z/d/drug information/121885.html" rel="external">Imipenem-cilastatin-relebactam</a>'s safety and efficacy was evaluated in the RESTORE-IMI 1 study where it was compared to an <a class="drug drug_general" data-topicid="8553" href="/z/d/drug information/8553.html" rel="external">imipenem</a>/<a class="drug drug_general" data-topicid="8718" href="/z/d/drug information/8718.html" rel="external">colistin</a> combination in the treatment of multiple infections, 35.5 percent of which were HAP/VAP, with the most common pathogen being <em>P. aeruginosa</em> (77.4 percent) [<a href="#rid60">60</a>]. Its efficacy was re-affirmed in RESTORE IMI 2 where imipenem-cilstatin-relebactam was compared to <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">piperacillin-tazobactam</a> in the treatment of HAP/VAP [<a href="#rid61">61</a>].</p><p>Real-world data evaluating <a class="drug drug_general" data-topicid="121885" href="/z/d/drug information/121885.html" rel="external">imipenem-cilastatin-relebactam</a> is scarce [<a href="#rid62">62,63</a>]. However, studies done so far have also demonstrated the high efficacy and safety of this BL-BLI. In a multi-center observational study of 21 patients, where the most commonly evaluated infection was respiratory tract infection (52 percent HAP/VAP) and the most common pathogen was MDR <em>P. aeruginosa</em> (76 percent), 30-day mortality was 33 percent, which was attributed to patients having comorbidities, whereas clinical cure was 62 percent. As for side effects, only gastrointestinal symptoms and one case of encephalopathy were reported, neither leading to drug discontinuation [<a href="#rid62">62</a>]. </p><p>Cross-resistance remains an issue in regard to <a class="drug drug_general" data-topicid="98763" href="/z/d/drug information/98763.html" rel="external">ceftolozane-tazobactam</a> and <a class="drug drug_general" data-topicid="100152" href="/z/d/drug information/100152.html" rel="external">ceftazidime-avibactam</a> because of high structural similarities. Accordingly, the IDSA recommended in their recent guidance to always repeat antimicrobial susceptibility testing for newer BL-BLIs when a previously infected patient with difficult-to-treat <em>P. aeruginosa</em> presents with new or relapsed infection, with the consideration of the use of <a class="drug drug_general" data-topicid="121885" href="/z/d/drug information/121885.html" rel="external">imipenem-cilastatin-relebactam</a> or <a class="drug drug_general" data-topicid="126182" href="/z/d/drug information/126182.html" rel="external">cefiderocol</a> if the patient was recently treated with ceftolozane-tazobactam or ceftazidime-avibactam [<a href="#rid64">64</a>].</p><p><a class="drug drug_general" data-topicid="126182" href="/z/d/drug information/126182.html" rel="external">Cefiderocol</a>, a new siderophore cephalosporin, has also demonstrated noninferiority in the treatment of nosocomial pneumonia due to MDR GNB, 16 percent of which were secondary to <em>P. aeruginosa</em> when compared to <a class="drug drug_general" data-topicid="9613" href="/z/d/drug information/9613.html" rel="external">meropenem</a> in terms of all-cause mortality at 14 days [<a href="#rid65">65</a>].</p><p>Real-world data on <a class="drug drug_general" data-topicid="126182" href="/z/d/drug information/126182.html" rel="external">cefiderocol</a> use remains scarce [<a href="#rid66">66-68</a>]. In the largest recently performed retrospective multi-center cohort study to date that included 142 patients, 51.1 percent of who were diagnosed with pneumonia with 21.1 percent of all isolates being identified as <em>P. aeruginosa</em>, 30-day mortality was shown to be 37 percent, with a higher absolute rate of death in patients diagnosed with pneumonia (43 percent) [<a href="#rid68">68</a>].</p><p>Interestingly, in a study evaluating cross-resistance in <em>P. aeruginosa</em> isolates from patients treated with the new BL-BLIs, cross-resistance between <a class="drug drug_general" data-topicid="126182" href="/z/d/drug information/126182.html" rel="external">cefiderocol</a> and <a class="drug drug_general" data-topicid="98763" href="/z/d/drug information/98763.html" rel="external">ceftolozane-tazobactam</a> was evident, unlike with <a class="drug drug_general" data-topicid="100152" href="/z/d/drug information/100152.html" rel="external">ceftazidime-avibactam</a> and imipenem-relebactam [<a href="#rid69">69</a>].</p><p>Multiple antibiotics are currently in the pipeline, such as cefepime-taniborbactam, cefepime-zidebactam, cefepime-enmetazobactam, sulbactam durlobactam, and murepavadin [<a href="#rid70">70</a>]. All of these antibiotics, despite variable activity against carbapenemases, have demonstrated in vitro activity against drug-resistant <em>P. aeruginosa </em>[<a href="#rid71">71-75</a>], with cefepime-taniborbactam amd cefepime-zidebactam demonstrating in vivo bactericidal activity in murine lung infection models [<a href="#rid76">76,77</a>]. These antibiotics are yet to be assessed for nosocomial pneumonia.</p><p>Murepavadin is a new class antibiotic that selectively inhibits the lipopolysaccharide (LPS) protein D, a vital outer membrane protein involved in LPS biogenesis in Gram negative bacteria. It has demonstrated specific antimicrobial activity against multiple <em>Pseudomonas</em> spp including <em>P. aeruginosa </em>[<a href="#rid78">78</a>]. It was being evaluated in two clinical trials, PRISM-MDR and PRISM-UDR; however, both trials were stopped due to significant nephrotoxicity with further investigation of the molecule's safety required [<a href="#rid79">79,80</a>].</p><p>Although some experts continue a combination regimen as directed therapy in order to minimize the emergence of antimicrobial resistance, there is little clinical evidence that clearly demonstrates a benefit to directed combination therapy.</p><p>In a multicenter study of 183 patients with VAP due to <em>P. aeruginosa</em>, use of combination therapy or monotherapy tailored to susceptibility results did not influence mortality, length of stay, recurrent infection rate, or development of resistance [<a href="#rid81">81</a>]. In addition, a recent study based on the patients included in the iDIAPASON trial, a multi-center randomized controlled trial comparing 8- to 15-day antibiotic therapy for VAP secondary to <em>P. aeruginosa</em>, assessed the outcomes of using mono- versus combination therapy and no difference was found [<a href="#rid82">82</a>]. Moreover, real-world data on the use of novel BL-BLIs and <a class="drug drug_general" data-topicid="126182" href="/z/d/drug information/126182.html" rel="external">cefiderocol</a> as part of combination therapy have shown no difference in clinical outcomes [<a href="#rid57">57,58,68</a>]. In their latest update of guidelines for the treatment of resistant organisms, the IDSA recommended against using directed combination therapy in the treatment of difficult-to-treat <em>P. aeruginosa</em>, especially if the organism is susceptible to one of the new BL-BLIs [<a href="#rid64">64</a>]. (See  <a class="medical medical_review" href="/z/d/html/3135.html" rel="external">"Principles of antimicrobial therapy of Pseudomonas aeruginosa infections", section on 'Role of combination antimicrobial therapy'</a>.)</p><p class="headingAnchor" id="H1410972"><span class="h3">Duration of therapy</span><span class="headingEndMark"> — </span>The optimal duration of antimicrobial therapy for <em>P. aeruginosa</em> pneumonia is uncertain. We individualize the duration based on the underlying comorbidities and condition of the patient, the initial response to therapy, and the susceptibility of the infecting isolate. Patients who have no significant comorbidities, defervesce, and improve clinically within the first week of therapy, and those who have infection with a susceptible <em>P. aeruginosa</em> isolate, can be treated with regimens as short as 7 to 10 days. However, longer treatment durations (eg, from 10 to 21 days) may be warranted for patients with serious underlying conditions (eg, neutropenia), concurrent blood stream infection, a poor or slow response to therapy, and/or a partially susceptible or multidrug-resistant strain. If the isolate is susceptible to fluoroquinolones and there are no concerns about gastrointestinal absorption of oral medications, the patient can transition to oral <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">ciprofloxacin</a> or <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">levofloxacin</a> to complete the course.</p><p>Support for a relatively abbreviated course of antibiotics comes from several trials on treatment of VAP, in which short (seven- to eight-day) courses of antibiotics resulted in similar clinical cure and mortality rates and lower rates of recurrence with multidrug-resistant organisms compared with longer (10- to 15-day) courses [<a href="#rid83">83,84</a>]. However, in some studies, the recurrence rate for pneumonias caused by nonfermenting gram-negative bacilli (such as <em>P. aeruginosa</em>) was higher with short courses. This finding was re-demonstrated in the iDIAPASON study, a prospective multi-center randomized controlled open-label trial where the percentage of recurrence of ventilator-associated <em>P. aeruginosa</em> during the ICU stay was 9.2 percent in the 15-day group versus 17 percent in the 8-day group [<a href="#rid85">85</a>]. However, the duration of therapy remains a matter of debate. In a recent editorial, panelists who participated in the 2016 IDSA/ATS guidelines on ventilator-associated/HAP responded to a viewpoint by Albin et al [<a href="#rid86">86</a>] arguing against the last IDSA/ATS guidelines recommending a short course of VAP secondary to <em>P. aerguinosa</em>. Metersky et al argued that both major studies that reported increased recurrence in short duration therapy were fully or partially open-label; both studies did not account for the differential time-at-risk bias, leading to patients in the short-course group being observed for recurrence at least 7 to 10 days more than the opposing group. In addition, recurrence was not adequately assessed as both studies showed no difference in length of stay, mechanical ventilator duration, or mortality [<a href="#rid87">87</a>]. Thus, while a short course may be appropriate for some patients with <em>P. aeruginosa</em> pneumonia, we favor a more conservative approach with a longer course of therapy in patients who may have an especially high mortality because of comorbidities or according to the clinical course.</p><p>The airway may remain colonized with <em>P. aeruginosa</em> even in the setting of clinical response. Symptomatic improvement is a more important indicator than organism eradication for decisions regarding timing of antibiotic discontinuation.</p><p class="headingAnchor" id="H1210512861"><span class="h2">Inhaled antibiotics for selected patients</span><span class="headingEndMark"> — </span>We do not routinely use inhaled antibiotics for the treatment of <em>P. aeruginosa</em> pneumonia.</p><p>In their latest guidance on the management of antibiotic-resistant organisms, the IDSA did not recommend the use of nebulized antibiotics for the treatment of difficult-to-treat <em>P. aeruginosa</em> [<a href="#rid64">64</a>]. This is mainly due to the lack of evidence suggesting improved outcomes or higher survival rates even in subgroup analysis of resistant isolates, regardless of the medication used (<a class="drug drug_general" data-topicid="8718" href="/z/d/drug information/8718.html" rel="external">colistin</a>, <a class="drug drug_general" data-topicid="8536" href="/z/d/drug information/8536.html" rel="external">amikacin</a>, <a class="drug drug_general" data-topicid="8477" href="/z/d/drug information/8477.html" rel="external">fosfomycin</a>) [<a href="#rid88">88-90</a>], in addition to concerns that these medications may be causing damage to lung tissue. Similarly, the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) did not recommend inhaled antibiotic therapy due to the lack of strong evidence of efficacy [<a href="#rid91">91</a>]. Nevertheless, inhaled antibiotics can be used as an adjunct to intravenous therapy (IV) in cases of infection due to multidrug-resistant strains. </p><p>Specifically, inhaled polymyxins have been used successfully in the management of multidrug-resistant <em>P. aeruginosa</em> pneumonia failing to improve on IV therapy [<a href="#rid92">92-95</a>]. In a retrospective study from Italy of patients with VAP due to gram-negative organisms sensitive only to <a class="drug drug_general" data-topicid="8718" href="/z/d/drug information/8718.html" rel="external">colistin</a>, clinical cure rates were higher (69 versus 55 percent, p = 0.03) and duration of post-VAP mechanical ventilation shorter (median 8 versus 12 days) among 104 patients (24 with <em>P. aeruginosa</em>) who received nebulized and IV colistin compared with 104 matched patients (28 with <em>P. aeruginosa</em>) who received only IV colistin [<a href="#rid95">95</a>]. Nebulized colistin in treatment of pneumonia due to multidrug-resistant <em>Acinetobacter baumannii</em> and <em>P. aeruginosa</em> was evaluated in a retrospective study of 21 patients in Singapore [<a href="#rid93">93</a>]. Overall clinical and microbiological response rates were 57 and 86 percent, respectively. Most patients received 1 million units (approximately 80 mg) of colistin twice daily. There was no significant change in renal function or observed neurotoxicity. (See  <a class="medical medical_review" href="/z/d/html/486.html" rel="external">"Polymyxins: An overview"</a>.)</p><p><a class="drug drug_general" data-topicid="8718" href="/z/d/drug information/8718.html" rel="external">Colistin</a> is approved by the FDA only for IV or intramuscular use; it is not approved as a liquid to be inhaled via nebulizer. When the drug is mixed into a liquid form, the product can break down into other chemicals that can damage lung tissue [<a href="#rid96">96</a>]. Instructions regarding preparation of nebulized colistin are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/486.html" rel="external">"Polymyxins: An overview"</a>.) </p><p class="headingAnchor" id="H1410951"><span class="h2">Other strategies for drug-resistant isolates</span><span class="headingEndMark"> — </span>Drug-resistant <em>P. aeruginosa</em> infections should be managed with the assistance of an expert in the treatment of multidrug-resistant pathogens. Strategies for such infections include the use of inhaled antibiotics, alternative intravenous agents, and certain combination regimens. These are discussed elsewhere. (See <a class="local">'Inhaled antibiotics for selected patients'</a> above and  <a class="medical medical_review" href="/z/d/html/3135.html" rel="external">"Principles of antimicrobial therapy of Pseudomonas aeruginosa infections", section on 'Management of multidrug-resistant organisms'</a>.)</p><p>Bacteriophage therapy has been described as potential treatment for extensively drug-resistant <em>P. aeruginosa</em> infections in scattered case reports, including cases of lung infection [<a href="#rid97">97-99</a>]. In one case report, it was used for seven days in addition to prolonged antibiotic therapy in a woman with extensive necrotizing <em>P. aeruginosa</em> pneumonia, with subsequent resolution of infection and microbiologic clearance; bacteriophage therapy was well tolerated without adverse events detected during or after therapy [<a href="#rid97">97</a>]. Its use in the literature has been mainly described as an adjunct to antibiotics with various formulations used [<a href="#rid100">100</a>]. For instance, in their article describing three case reports of bacteriophage therapy in lung transplant patients, Aslam et al mention a 67-year male who had two episodes of MDR <em>P. aeruginosa</em> pneumonia post-transplant treated with IV and nebulized phage therapy, used both therapeutically and as suppressive therapy [<a href="#rid101">101</a>]. In another report by Chen et al, a 68-year-old man with broncho-pleural fistula-associated empyema and pneumonia secondary to carbapenem-resistant <em>P. aeruginosa</em> was treated with both nebulized and intrapleural phage therapy for 24 days in addition to IV antibiotics. The pathogen was cleared, the patient clinically improved, and phage therapy was well tolerated [<a href="#rid102">102</a>].</p><p>Other potential strategies under investigation for control of <em>P. aeruginosa</em> pneumonia include immunotherapy and vaccination. These are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3142.html" rel="external">"Epidemiology, microbiology, and pathogenesis of Pseudomonas aeruginosa infection", section on 'Investigational interventions based on pathogenesis'</a>.)</p><p class="headingAnchor" id="H13"><span class="h1">OUTCOME AND PROGNOSIS</span><span class="headingEndMark"> — </span><em>P. aeruginosa</em> pneumonia is associated with high in-hospital mortality rates and prolonged lengths of stay [<a href="#rid4">4,29</a>]. Injury to the alveolar epithelium allows the release of proinflammatory mediators into the circulation that are primarily responsible for septic shock [<a href="#rid103">103</a>]. (See  <a class="medical medical_review" href="/z/d/html/1657.html" rel="external">"Sepsis syndromes in adults: Epidemiology, definitions, clinical presentation, diagnosis, and prognosis"</a>.)</p><p><em>P. aeruginosa</em> pneumonia accompanied by <em>P. aeruginosa</em> bacteremia is associated with a particularly poor prognosis, with death occurring three to four days after the first signs of infection in the majority of cases.</p><p>Other factors significantly associated with a poor prognosis include [<a href="#rid4">4,104-106</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Advanced age</p><p class="bulletIndent1"><span class="glyph">●</span>Serious underlying disease</p><p class="bulletIndent1"><span class="glyph">●</span>Septic shock</p><p class="bulletIndent1"><span class="glyph">●</span>Acute respiratory distress syndrome</p><p class="bulletIndent1"><span class="glyph">●</span>Previous surgery </p><p class="bulletIndent1"><span class="glyph">●</span>Comorbidities, such as diabetes mellitus</p><p class="bulletIndent1"><span class="glyph">●</span>Inadequate initial antibiotic therapy</p><p class="bulletIndent1"><span class="glyph">●</span>Use of broad-spectrum antibiotics in previous six months</p><p class="bulletIndent1"><span class="glyph">●</span>Multidrug-resistant organisms</p><p></p><p>As an example, in a study of 110 ICU patients with culture confirmed <em>P. aeruginosa</em> pneumonia, inadequate initial antibiotic therapy, diabetes mellitus, disease severity (high Simplified Acute Physiology Score [SAPS] II), and older age were independently associated with ICU mortality [<a href="#rid106">106</a>]. Among survivors, inappropriate initial antibiotic therapy and infection with multidrug-resistant <em>P. aeruginosa</em> infection were each associated with longer post-pneumonia mechanical ventilation time.</p><p>In one retrospective study of patients with hospital-acquired <em>P. aeruginosa</em> pneumonia, receipt of inadequate initial antibiotic therapy was associated with a substantially higher mortality rate compared with adequate therapy (64 versus 25 percent) [<a href="#rid106">106</a>]. </p><p class="headingAnchor" id="H371766596"><span class="h1">PSEUDOMONAS IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE</span><span class="headingEndMark"> — </span>Isolation of <em>P. aeruginosa</em> from sputum samples of adult patients with COPD is associated with advanced pulmonary disease [<a href="#rid107">107</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>In one cross-sectional study, patients with a predicted FEV1 of less than 50 percent were more likely to have H. influenzae or <em>P. aeruginosa </em>isolated from sputum during exacerbations than patients with less severe impairment of pulmonary function [<a href="#rid108">108</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Another study demonstrated that in patients who had FEV1 less than 35 percent the predicted value, Enterobacterales and <em>Pseudomonas</em> species were the predominant isolated bacteria from sputum [<a href="#rid109">109</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a separate study, the presence of enteric gram-negative bacilli and <em>P. aeruginosa</em> in the sputum of patients during exacerbations could be predicted by severe airflow obstruction [<a href="#rid110">110</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Furthermore, exacerbations in the presence of <em>P. aeruginosa</em> in the sputum are linked to respiratory failure and the need for mechanical ventilation. These interpretations may suggest that <em>P. aeruginosa</em> is a more frequent cause of infection as COPD progresses.</p><p></p><p>There exists a subset of patients with COPD who become chronically colonized with <em>P. aeruginosa</em>, but whether such patients benefit from antimicrobial therapy is still unclear.</p><p class="headingAnchor" id="H469449585"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hospital-acquired pneumonia</strong> – <em>P. aeruginosa</em> is a common cause of gram-negative hospital-acquired pneumonia, which can occur via aspiration of endogenous oral flora, via aspiration of organisms from contaminated ventilator tubing or other health care devices, or through hematogenous spread. (See <a class="local">'Hospital-acquired pneumonia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Community-acquired pneumonia</strong> – Community-acquired <em>P. aeruginosa</em> pneumonia occurs mainly in immunocompromised patients (eg, HIV-infected patients, solid organ or stem cell transplant recipients, or neutropenic hosts), those with recent prior antibiotic use, and those with structural lung abnormalities such as cystic fibrosis, bronchiectasis, or repeated exacerbations of chronic obstructive pulmonary disease requiring frequent glucocorticoid and/or antibiotic use. (See <a class="local">'Community-acquired pneumonia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> – <em>P. aeruginosa</em> pneumonia is usually characterized by cough productive of purulent sputum, dyspnea, fever, chills, confusion, and severe systemic toxicity. None of these manifestations firmly distinguish this infection from pneumonia caused by other pyogenic organisms or Legionella. Radiographic findings are variable and no single finding is predictive or characteristic of <em>P. aeruginosa</em> pneumonia. (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of <em>P. aeruginosa</em> pneumonia is made following the growth of <em>P. aeruginosa</em> on culture of expectorated sputum, bronchoscopically-obtained samples, or other respiratory specimens in a patient with clinical and radiographic findings consistent with pneumonia. (See <a class="local">'Diagnosis'</a> above and  <a class="medical medical_review" href="/z/d/html/7020.html" rel="external">"Epidemiology, pathogenesis, microbiology, and diagnosis of hospital-acquired and ventilator-associated pneumonia in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Empiric antibiotic selection</strong> – Until antimicrobial susceptibility results are available, suspected cases of <em>P. aeruginosa</em> pneumonia can be empirically treated with a single antimicrobial agent, unless the patient has sepsis or risk factors for a drug resistant infection, in which case we use two antibiotics from different classes to which the isolate is likely to be susceptible  (<a class="graphic graphic_table graphicRef91115" href="/z/d/graphic/91115.html" rel="external">table 1</a>). The rationale for combination versus monotherapy is discussed elsewhere. (See <a class="local">'Empiric antimicrobial therapy'</a> above and  <a class="medical medical_review" href="/z/d/html/3135.html" rel="external">"Principles of antimicrobial therapy of Pseudomonas aeruginosa infections", section on 'Role of combination antimicrobial therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Targeted antibiotics</strong> – Once susceptibility testing results are available, we suggest use of a single active antibiotic for directed therapy of susceptible infections instead of combination therapy (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). Patients who have no significant comorbidities, defervesce and improve clinically within the first week of therapy, and those who have infection with a susceptible <em>P. aeruginosa</em> isolate can be treated with regimens as short as 7 to 10 days. Longer treatment durations (eg, from 10 to 21 days) may be warranted for other patients. (See <a class="local">'Directed antimicrobial therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of multidrug resistance</strong> – Multidrug-resistant <em>P. aeruginosa</em> infections should be managed with the assistance of an expert in the treatment of such infections. Alternative agents such as <a class="drug drug_general" data-topicid="8718" href="/z/d/drug information/8718.html" rel="external">colistin</a> may be necessary. Other possible strategies for resistant infections include the use of inhaled antibiotics, combination regimens, and alternative dosing strategies. (See <a class="local">'Inhaled antibiotics for selected patients'</a> above and  <a class="medical medical_review" href="/z/d/html/3135.html" rel="external">"Principles of antimicrobial therapy of Pseudomonas aeruginosa infections", section on 'Management of multidrug-resistant organisms'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – <em>P. aeruginosa</em> pneumonia is associated with high in-hospital mortality rates and prolonged lengths of stay. (See <a class="local">'Outcome and prognosis'</a> above.)</p><p></p><p class="headingAnchor" id="H2367088423"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Daniel Sexton, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Weber DJ, Rutala WA, Sickbert-Bennett EE, et al. Microbiology of ventilator-associated pneumonia compared with that of hospital-acquired pneumonia. Infect Control Hosp Epidemiol 2007; 28:825.</a></li><li><a class="nounderline abstract_t">Nseir S, Di Pompeo C, Pronnier P, et al. Nosocomial tracheobronchitis in mechanically ventilated patients: incidence, aetiology and outcome. Eur Respir J 2002; 20:1483.</a></li><li><a class="nounderline abstract_t">Rello J, Quintana E, Ausina V, et al. Incidence, etiology, and outcome of nosocomial pneumonia in mechanically ventilated patients. Chest 1991; 100:439.</a></li><li><a class="nounderline abstract_t">Crabtree TD, Gleason TG, Pruett TL, Sawyer RG. Trends in nosocomial pneumonia in surgical patients as we approach the 21st century: a prospective analysis. Am Surg 1999; 65:706.</a></li><li><a class="nounderline abstract_t">Gales AC, Sader H HS, Jones RN. Respiratory tract pathogens isolated from patients hospitalized with suspected pneumonia in Latin America: frequency of occurrence and antimicrobial susceptibility profile: results from the SENTRY Antimicrobial Surveillance Program (1997-2000). Diagn Microbiol Infect Dis 2002; 44:301.</a></li><li><a class="nounderline abstract_t">Rello J, Borgatta B, Lisboa T. Risk factors for Pseudomonas aeruginosa pneumonia in the early twenty-first century. Intensive Care Med 2013; 39:2204.</a></li><li><a class="nounderline abstract_t">Neuhauser MM, Weinstein RA, Rydman R, et al. Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA 2003; 289:885.</a></li><li><a class="nounderline abstract_t">Agodi A, Barchitta M, Cipresso R, et al. Pseudomonas aeruginosa carriage, colonization, and infection in ICU patients. Intensive Care Med 2007; 33:1155.</a></li><li><a class="nounderline abstract_t">Vallés J, Mariscal D, Cortés P, et al. Patterns of colonization by Pseudomonas aeruginosa in intubated patients: a 3-year prospective study of 1,607 isolates using pulsed-field gel electrophoresis with implications for prevention of ventilator-associated pneumonia. Intensive Care Med 2004; 30:1768.</a></li><li><a class="nounderline abstract_t">Kumar PD, Ravakhah K, West BC. Disseminated Pseudomonas aeruginosa and necrotizing pneumonia with complete recovery. South Med J 2001; 94:229.</a></li><li><a class="nounderline abstract_t">Venier AG, Gruson D, Lavigne T, et al. Identifying new risk factors for Pseudomonas aeruginosa pneumonia in intensive care units: experience of the French national surveillance, REA-RAISIN. J Hosp Infect 2011; 79:44.</a></li><li><a class="nounderline abstract_t">Restrepo MI, Babu BL, Reyes LF, et al. Burden and risk factors for Pseudomonas aeruginosa community-acquired pneumonia: a multinational point prevalence study of hospitalised patients. Eur Respir J 2018; 52.</a></li><li><a class="nounderline abstract_t">Henderson A, Kelly W, Wright M. Fulminant primary Pseudomonas aeruginosa pneumonia and septicaemia in previously well adults. Intensive Care Med 1992; 18:430.</a></li><li><a class="nounderline abstract_t">Barp N, Marcacci M, Biagioni E, et al. A Fatal Case of Pseudomonas aeruginosa Community-Acquired Pneumonia in an Immunocompetent Patient: Clinical and Molecular Characterization and Literature Review. Microorganisms 2023; 11.</a></li><li><a class="nounderline abstract_t">Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44 Suppl 2:S27.</a></li><li><a class="nounderline abstract_t">Arancibia F, Bauer TT, Ewig S, et al. Community-acquired pneumonia due to gram-negative bacteria and pseudomonas aeruginosa: incidence, risk, and prognosis. Arch Intern Med 2002; 162:1849.</a></li><li><a class="nounderline abstract_t">Lees CW, Heys D, Ho GT, et al. A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitis. Aliment Pharmacol Ther 2007; 26:411.</a></li><li><a class="nounderline abstract_t">López-Palomo C, Martín-Zamorano M, Benítez E, et al. Pneumonia in HIV-infected patients in the HAART era: incidence, risk, and impact of the pneumococcal vaccination. J Med Virol 2004; 72:517.</a></li><li><a class="nounderline abstract_t">Madeddu G, Porqueddu EM, Cambosu F, et al. Bacterial community acquired pneumonia in HIV-infected inpatients in the highly active antiretroviral therapy era. Infection 2008; 36:231.</a></li><li><a class="nounderline abstract_t">Lewis PO. Risk Factor Evaluation for Methicillin-Resistant Staphylococcus aureus and Pseudomonas aeruginosa in Community-Acquired Pneumonia. Ann Pharmacother 2021; 55:36.</a></li><li><a class="nounderline abstract_t">Viasus D, Garcia-Vidal C, Castellote J, et al. Community-acquired pneumonia in patients with liver cirrhosis: clinical features, outcomes, and usefulness of severity scores. Medicine (Baltimore) 2011; 90:110.</a></li><li><a class="nounderline abstract_t">Rello J, Rodriguez A, Torres A, et al. Implications of COPD in patients admitted to the intensive care unit by community-acquired pneumonia. Eur Respir J 2006; 27:1210.</a></li><li><a class="nounderline abstract_t">von Baum H, Welte T, Marre R, et al. Community-acquired pneumonia through Enterobacteriaceae and Pseudomonas aeruginosa: Diagnosis, incidence and predictors. Eur Respir J 2010; 35:598.</a></li><li><a class="nounderline abstract_t">Patel P, Whittier S, Frank E. Person-to-person transmission of Pseudomonas pneumonia in the community: documentation by pulsed-field electrophoresis. South Med J 2002; 95:653.</a></li><li><a class="nounderline abstract_t">Crnich CJ, Gordon B, Andes D. Hot tub-associated necrotizing pneumonia due to Pseudomonas aeruginosa. Clin Infect Dis 2003; 36:e55.</a></li><li><a class="nounderline abstract_t">Kirschke DL, Jones TF, Craig AS, et al. Pseudomonas aeruginosa and Serratia marcescens contamination associated with a manufacturing defect in bronchoscopes. N Engl J Med 2003; 348:214.</a></li><li><a class="nounderline abstract_t">Srinivasan A, Wolfenden LL, Song X, et al. An outbreak of Pseudomonas aeruginosa infections associated with flexible bronchoscopes. N Engl J Med 2003; 348:221.</a></li><li><a class="nounderline abstract_t">Engelhart S, Krizek L, Glasmacher A, et al. Pseudomonas aeruginosa outbreak in a haematology-oncology unit associated with contaminated surface cleaning equipment. J Hosp Infect 2002; 52:93.</a></li><li><a class="nounderline abstract_t">Fujitani S, Sun HY, Yu VL, Weingarten JA. Pneumonia due to Pseudomonas aeruginosa: part I: epidemiology, clinical diagnosis, and source. Chest 2011; 139:909.</a></li><li><a class="nounderline abstract_t">Di Pasquale M, Ferrer M, Esperatti M, et al. Assessment of severity of ICU-acquired pneumonia and association with etiology. Crit Care Med 2014; 42:303.</a></li><li><a class="nounderline abstract_t">Shah RM, Wechsler R, Salazar AM, Spirn PW. Spectrum of CT findings in nosocomial Pseudomonas aeruginosa pneumonia. J Thorac Imaging 2002; 17:53.</a></li><li><a class="nounderline abstract_t">Schuster MG, Norris AH. Community-acquired Pseudomonas aeruginosa pneumonia in patients with HIV infection. AIDS 1994; 8:1437.</a></li><li><a class="nounderline abstract_t">Bonifacio SL, Kitterman JA, Ursell PC. Pseudomonas pneumonia in infants: an autopsy study. Hum Pathol 2003; 34:929.</a></li><li><a class="nounderline abstract_t">Deschaght P, Schelstraete P, Van Simaey L, et al. Is the improvement of CF patients, hospitalized for pulmonary exacerbation, correlated to a decrease in bacterial load? PLoS One 2013; 8:e79010.</a></li><li><a class="nounderline abstract_t">American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171:388.</a></li><li><a class="nounderline abstract_t">Sader HS, Castanheira M, Duncan LR, Flamm RK. Antimicrobial Susceptibility of Enterobacteriaceae and Pseudomonas aeruginosa Isolates from United States Medical Centers Stratified by Infection Type: Results from the International Network for Optimal Resistance Monitoring (INFORM) Surveillance Program, 2015-2016. Diagn Microbiol Infect Dis 2018; 92:69.</a></li><li><a class="nounderline abstract_t">Kollef MH, Nováček M, Kivistik Ü, et al. Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis 2019; 19:1299.</a></li><li><a class="nounderline abstract_t">Rodríguez-Núñez O, Ripa M, Morata L, et al. Evaluation of ceftazidime/avibactam for serious infections due to multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa. J Glob Antimicrob Resist 2018; 15:136.</a></li><li><a class="nounderline abstract_t">Zingg S, Nicoletti GJ, Kuster S, et al. Cefiderocol for Extensively Drug-Resistant Gram-Negative Bacterial Infections: Real-world Experience From a Case Series and Review of the Literature. Open Forum Infect Dis 2020; 7:ofaa185.</a></li><li><a class="nounderline abstract_t">Munita JM, Aitken SL, Miller WR, et al. Multicenter Evaluation of Ceftolozane/Tazobactam for Serious Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa. Clin Infect Dis 2017.</a></li><li><a class="nounderline abstract_t">Gallagher JC, Satlin MJ, Elabor A, et al. Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: A Multicenter Study. Open Forum Infect Dis 2018; 5:ofy280.</a></li><li><a class="nounderline abstract_t">Bassetti M, Castaldo N, Cattelan A, et al. Ceftolozane/tazobactam for the treatment of serious Pseudomonas aeruginosa infections: a multicentre nationwide clinical experience. Int J Antimicrob Agents 2019; 53:408.</a></li><li><a class="nounderline abstract_t">Puzniak L, Dillon R, Palmer T, et al. Systematic Literature Review of Real-world Evidence of Ceftolozane/Tazobactam for the Treatment of Respiratory Infections. Infect Dis Ther 2021; 10:1227.</a></li><li><a class="nounderline abstract_t">Jorgensen SCJ, Trinh TD, Zasowski EJ, et al. Real-World Experience With Ceftazidime-Avibactam for Multidrug-Resistant Gram-Negative Bacterial Infections. Open Forum Infect Dis 2019; 6:ofz522.</a></li><li><a class="nounderline abstract_t">Tamma PD, Aitken SL, Bonomo RA, et al. Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa). Clin Infect Dis 2021; 72:e169.</a></li><li><a class="nounderline abstract_t">Johnson MG, Bruno C, Castanheira M, et al. Evaluating the emergence of nonsusceptibility among Pseudomonas aeruginosa respiratory isolates from a phase-3 clinical trial for treatment of nosocomial pneumonia (ASPECT-NP). Int J Antimicrob Agents 2021; 57:106278.</a></li><li><a class="nounderline abstract_t">Lodise T, Yang J, Puzniak LA, et al. Healthcare Resource Utilization of Ceftolozane/Tazobactam Versus Meropenem for Ventilated Nosocomial Pneumonia from the Randomized, Controlled, Double-Blind ASPECT-NP Trial. Infect Dis Ther 2020; 9:953.</a></li><li><a class="nounderline abstract_t">Pogue JM, Kaye KS, Veve MP, et al. Ceftolozane/Tazobactam vs Polymyxin or Aminoglycoside-based Regimens for the Treatment of Drug-resistant Pseudomonas aeruginosa. Clin Infect Dis 2020; 71:304.</a></li><li><a class="nounderline abstract_t">Mogyoródi B, Csékó AB, Hermann C, et al. Ceftolozane/tazobactam versus colistin in the treatment of ventilator-associated pneumonia due to extensively drug-resistant Pseudomonas aeruginosa. Sci Rep 2022; 12:4455.</a></li><li><a class="nounderline abstract_t">Almangour TA, Aljabri A, Al Musawa M, et al. Ceftolozane-tazobactam vs. colistin for the treatment of infections due to multidrug-resistant Pseudomonas aeruginosa: a multicentre cohort study. J Glob Antimicrob Resist 2022; 28:288.</a></li><li><a class="nounderline abstract_t">Leitão IL, Mimoso Santos C, André P, et al. Ceftolozane/tazobactam for the treatment of Pseudomonas aeruginosa infections: A multicenter case series analysis. Enferm Infecc Microbiol Clin (Engl Ed) 2023; 41:454.</a></li><li><a class="nounderline abstract_t">Holger DJ, Rebold NS, Alosaimy S, et al. Impact of Ceftolozane-Tazobactam vs. Best Alternative Therapy on Clinical Outcomes in Patients with Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Lower Respiratory Tract Infections. Infect Dis Ther 2022; 11:1965.</a></li><li><a class="nounderline abstract_t">Van Anglen LJ, Schroeder CP, Couch KA. A Real-world Multicenter Outpatient Experience of Ceftolozane/Tazobactam. Open Forum Infect Dis 2023; 10:ofad173.</a></li><li><a class="nounderline abstract_t">Torres A, Zhong N, Pachl J, et al. Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial. Lancet Infect Dis 2018; 18:285.</a></li><li><a class="nounderline abstract_t">Soriano A, Carmeli Y, Omrani AS, et al. Ceftazidime-Avibactam for the Treatment of Serious Gram-Negative Infections with Limited Treatment Options: A Systematic Literature Review. Infect Dis Ther 2021; 10:1989.</a></li><li><a class="nounderline abstract_t">Yu J, Zuo W, Fan H, et al. Ceftazidime-Avibactam for Carbapenem-Resistant Gram-Negative Bacteria Infections: A Real-World Experience in the ICU. Infect Drug Resist 2023; 16:6209.</a></li><li><a class="nounderline abstract_t">Xu C, Zeng F, Huang Y, et al. Clinical efficacy of ceftazidime/avibactam combination therapy for severe hospital-acquired pulmonary infections caused by carbapenem-resistant and difficult-to-treat Pseudomonas aeruginosa. Int J Antimicrob Agents 2024; 63:107021.</a></li><li><a class="nounderline abstract_t">Corbella L, Boán J, San-Juan R, et al. Effectiveness of ceftazidime-avibactam for the treatment of infections due to Pseudomonas aeruginosa. Int J Antimicrob Agents 2022; 59:106517.</a></li><li><a class="nounderline abstract_t">Almangour TA, Ghonem L, Alassiri D, et al. Ceftolozane-Tazobactam Versus Ceftazidime-Avibactam for the Treatment of Infections Caused by Multidrug-Resistant Pseudomonas aeruginosa: a Multicenter Cohort Study. Antimicrob Agents Chemother 2023; 67:e0040523.</a></li><li><a class="nounderline abstract_t">Sellarès-Nadal J, Eremiev S, Burgos J, Almirante B. An overview of cilastatin + imipenem + relebactam as a therapeutic option for hospital-acquired and ventilator-associated bacterial pneumonia: evidence to date. Expert Opin Pharmacother 2021; 22:1521.</a></li><li><a class="nounderline abstract_t">Titov I, Wunderink RG, Roquilly A, et al. A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study). Clin Infect Dis 2021; 73:e4539.</a></li><li><a class="nounderline abstract_t">Rebold N, Morrisette T, Lagnf AM, et al. Early Multicenter Experience With Imipenem-Cilastatin-Relebactam for Multidrug-Resistant Gram-Negative Infections. Open Forum Infect Dis 2021; 8:ofab554.</a></li><li><a class="nounderline abstract_t">Shields RK, Stellfox ME, Kline EG, et al. Evolution of Imipenem-Relebactam Resistance Following Treatment of Multidrug-Resistant Pseudomonas aeruginosa Pneumonia. Clin Infect Dis 2022; 75:710.</a></li><li><a class="nounderline abstract_t">Tamma PD, Aitken SL, Bonomo RA, et al. Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections. Clin Infect Dis 2023.</a></li><li><a class="nounderline abstract_t">Wunderink RG, Matsunaga Y, Ariyasu M, et al. Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis 2021; 21:213.</a></li><li><a class="nounderline abstract_t">de la Fuente C, Rodríguez M, Merino N, et al. Real-life use of cefiderocol for salvage therapy of severe infections due to carbapenem-resistant Gram-negative bacteria. Int J Antimicrob Agents 2023; 62:106818.</a></li><li><a class="nounderline abstract_t">Fendian ÁM, Albanell-Fernández M, Tuset M, et al. Real-Life Data on the Effectiveness and Safety of Cefiderocol in Severely Infected Patients: A Case Series. Infect Dis Ther 2023; 12:1205.</a></li><li><a class="nounderline abstract_t">Piccica M, Spinicci M, Botta A, et al. Cefiderocol use for the treatment of infections by carbapenem-resistant Gram-negative bacteria: an Italian multicentre real-life experience. J Antimicrob Chemother 2023; 78:2752.</a></li><li><a class="nounderline abstract_t">Shields RK, Kline EG, Squires KM, et al. In vitro activity of cefiderocol against Pseudomonas aeruginosa demonstrating evolved resistance to novel β-lactam/β-lactamase inhibitors. JAC Antimicrob Resist 2023; 5:dlad107.</a></li><li><a class="nounderline abstract_t">Bassetti M, Castaldo N, Fantin A, et al. Antibiotic therapy for nonfermenting Gram-negative bacilli infections: future perspectives. Curr Opin Infect Dis 2023; 36:615.</a></li><li><a class="nounderline abstract_t">Kloezen W, Melchers RJ, Georgiou PC, et al. Activity of Cefepime in Combination with the Novel β-Lactamase Inhibitor Taniborbactam (VNRX-5133) against Extended-Spectrum-β-Lactamase-Producing Isolates in In Vitro Checkerboard Assays. Antimicrob Agents Chemother 2021; 65.</a></li><li><a class="nounderline abstract_t">Hernández-García M, García-Castillo M, Ruiz-Garbajosa P, et al. In Vitro Activity of Cefepime-Taniborbactam against Carbapenemase-Producing Enterobacterales and Pseudomonas aeruginosa Isolates Recovered in Spain. Antimicrob Agents Chemother 2022; 66:e0216121.</a></li><li><a class="nounderline abstract_t">Khan Z, Iregui A, Landman D, Quale J. Activity of cefepime/zidebactam (WCK 5222) against Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter baumannii endemic to New York City medical centres. J Antimicrob Chemother 2019; 74:2938.</a></li><li><a class="nounderline abstract_t">Isler B, Harris P, Stewart AG, Paterson DL. An update on cefepime and its future role in combination with novel β-lactamase inhibitors for MDR Enterobacterales and Pseudomonas aeruginosa. J Antimicrob Chemother 2021; 76:550.</a></li><li><a class="nounderline abstract_t">Durand-Réville TF, Guler S, Comita-Prevoir J, et al. ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii. Nat Microbiol 2017; 2:17104.</a></li><li><a class="nounderline abstract_t">Abdelraouf K, Nicolau DP. In vivo pharmacokinetic/pharmacodynamic evaluation of cefepime/taniborbactam combination against cefepime-non-susceptible Enterobacterales and Pseudomonas aeruginosa in a murine pneumonia model. J Antimicrob Chemother 2023; 78:692.</a></li><li><a class="nounderline abstract_t">Monogue ML, Tabor-Rennie J, Abdelraouf K, Nicolau DP. In Vivo Efficacy of WCK 5222 (Cefepime-Zidebactam) against Multidrug-Resistant Pseudomonas aeruginosa in the Neutropenic Murine Thigh Infection Model. Antimicrob Agents Chemother 2019; 63.</a></li><li><a class="nounderline abstract_t">Sader HS, Dale GE, Rhomberg PR, Flamm RK. Antimicrobial Activity of Murepavadin Tested against Clinical Isolates of Pseudomonas aeruginosa from the United States, Europe, and China. Antimicrob Agents Chemother 2018; 62.</a></li><li class="breakAll">Pivotal Study in VAP Suspected or Confirmed to be Due to Pseudomonas Aeruginosa (PRISM-MDR). ClinicalTrials.gov, identifier: NCT03409679. Available at: https://clinicaltrials.gov/study/NCT03409679?term=NCT03409679&amp;rank=1 (Accessed on November 14, 2023).</li><li class="breakAll">Pivotal Study in Nosocomial Pneumonia Suspected or Confirmed to be Due to Pseudomonas (PRISM-UDR). ClinicalTrials.gov, identifier: NCT03582007. Available at: https://clinicaltrials.gov/study/NCT03582007?term=NCT03582007&amp;rank=1 (Accessed on November 14, 2023).</li><li><a class="nounderline abstract_t">Garnacho-Montero J, Sa-Borges M, Sole-Violan J, et al. Optimal management therapy for Pseudomonas aeruginosa ventilator-associated pneumonia: an observational, multicenter study comparing monotherapy with combination antibiotic therapy. Crit Care Med 2007; 35:1888.</a></li><li><a class="nounderline abstract_t">Foucrier A, Dessalle T, Tuffet S, et al. Association between combination antibiotic therapy as opposed as monotherapy and outcomes of ICU patients with Pseudomonas aeruginosa ventilator-associated pneumonia: an ancillary study of the iDIAPASON trial. Crit Care 2023; 27:211.</a></li><li><a class="nounderline abstract_t">Pugh R, Grant C, Cooke RP, Dempsey G. Short-course versus prolonged-course antibiotic therapy for hospital-acquired pneumonia in critically ill adults. Cochrane Database Syst Rev 2015; :CD007577.</a></li><li><a class="nounderline abstract_t">Chastre J, Wolff M, Fagon JY, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 2003; 290:2588.</a></li><li><a class="nounderline abstract_t">Bouglé A, Tuffet S, Federici L, et al. Comparison of 8 versus 15 days of antibiotic therapy for Pseudomonas aeruginosa ventilator-associated pneumonia in adults: a randomized, controlled, open-label trial. Intensive Care Med 2022; 48:841.</a></li><li><a class="nounderline abstract_t">Albin OR, Kaye KS, McCreary EK, Pogue JM. Less Is More? Antibiotic Treatment Duration in Pseudomonas aeruginosa Ventilator-Associated Pneumonia. Clin Infect Dis 2023; 76:745.</a></li><li><a class="nounderline abstract_t">Metersky ML, Klompas M, Kalil AC. Less Is More: A 7-Day Course of Antibiotics Is the Evidence-Based Treatment for Pseudomonas aeruginosa Ventilator-Associated Pneumonia. Clin Infect Dis 2023; 76:750.</a></li><li><a class="nounderline abstract_t">Rattanaumpawan P, Lorsutthitham J, Ungprasert P, et al. Randomized controlled trial of nebulized colistimethate sodium as adjunctive therapy of ventilator-associated pneumonia caused by Gram-negative bacteria. J Antimicrob Chemother 2010; 65:2645.</a></li><li><a class="nounderline abstract_t">Kollef MH, Ricard JD, Roux D, et al. A randomized trial of the amikacin fosfomycin inhalation system for the adjunctive therapy of Gram-negative ventilator-associated pneumonia: IASIS Trial. Chest 2016.</a></li><li><a class="nounderline abstract_t">Niederman MS, Alder J, Bassetti M, et al. Inhaled amikacin adjunctive to intravenous standard-of-care antibiotics in mechanically ventilated patients with Gram-negative pneumonia (INHALE): a double-blind, randomised, placebo-controlled, phase 3, superiority trial. Lancet Infect Dis 2020; 20:330.</a></li><li><a class="nounderline abstract_t">Rello J, Solé-Lleonart C, Rouby JJ, et al. Use of nebulized antimicrobials for the treatment of respiratory infections in invasively mechanically ventilated adults: a position paper from the European Society of Clinical Microbiology and Infectious Diseases. Clin Microbiol Infect 2017; 23:629.</a></li><li><a class="nounderline abstract_t">Pereira GH, Muller PR, Levin AS. Salvage treatment of pneumonia and initial treatment of tracheobronchitis caused by multidrug-resistant Gram-negative bacilli with inhaled polymyxin B. Diagn Microbiol Infect Dis 2007; 58:235.</a></li><li><a class="nounderline abstract_t">Kwa AL, Loh C, Low JG, et al. Nebulized colistin in the treatment of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Clin Infect Dis 2005; 41:754.</a></li><li><a class="nounderline abstract_t">Hamer DH. Treatment of nosocomial pneumonia and tracheobronchitis caused by multidrug-resistant Pseudomonas aeruginosa with aerosolized colistin. Am J Respir Crit Care Med 2000; 162:328.</a></li><li><a class="nounderline abstract_t">Tumbarello M, De Pascale G, Trecarichi EM, et al. Effect of aerosolized colistin as adjunctive treatment on the outcomes of microbiologically documented ventilator-associated pneumonia caused by colistin-only susceptible gram-negative bacteria. Chest 2013; 144:1768.</a></li><li class="breakAll">www.fda.gov/cder/drug/advisory/colistimethate.htm (Accessed on July 30, 2007).</li><li><a class="nounderline abstract_t">Maddocks S, Fabijan AP, Ho J, et al. Bacteriophage Therapy of Ventilator-associated Pneumonia and Empyema Caused by Pseudomonas aeruginosa. Am J Respir Crit Care Med 2019; 200:1179.</a></li><li><a class="nounderline abstract_t">Law N, Logan C, Yung G, et al. Successful adjunctive use of bacteriophage therapy for treatment of multidrug-resistant Pseudomonas aeruginosa infection in a cystic fibrosis patient. Infection 2019; 47:665.</a></li><li><a class="nounderline abstract_t">Dan JM, Lehman SM, Al-Kolla R, et al. Development of Host Immune Response to Bacteriophage in a Lung Transplant Recipient on Adjunctive Phage Therapy for a Multidrug-Resistant Pneumonia. J Infect Dis 2023; 227:311.</a></li><li><a class="nounderline abstract_t">Santamaría-Corral G, Senhaji-Kacha A, Broncano-Lavado A, et al. Bacteriophage-Antibiotic Combination Therapy against Pseudomonas aeruginosa. Antibiotics (Basel) 2023; 12.</a></li><li><a class="nounderline abstract_t">Aslam S, Courtwright AM, Koval C, et al. Early clinical experience of bacteriophage therapy in 3 lung transplant recipients. Am J Transplant 2019; 19:2631.</a></li><li><a class="nounderline abstract_t">Chen P, Liu Z, Tan X, et al. Bacteriophage therapy for empyema caused by carbapenem-resistant Pseudomonas aeruginosa. Biosci Trends 2022; 16:158.</a></li><li><a class="nounderline abstract_t">Kurahashi K, Kajikawa O, Sawa T, et al. Pathogenesis of septic shock in Pseudomonas aeruginosa pneumonia. J Clin Invest 1999; 104:743.</a></li><li><a class="nounderline abstract_t">Martínez B, Gómez J, Gómez Vargas J, et al. [Risk factors and prognosis of nosocomial pneumonia due to gram-negative bacteria in a general hospital]. Rev Esp Quimioter 2000; 13:187.</a></li><li><a class="nounderline abstract_t">Wang CY, Jerng JS, Chen KY, et al. Pandrug-resistant Pseudomonas aeruginosa among hospitalised patients: clinical features, risk-factors and outcomes. Clin Microbiol Infect 2006; 12:63.</a></li><li><a class="nounderline abstract_t">Tumbarello M, De Pascale G, Trecarichi EM, et al. Clinical outcomes of Pseudomonas aeruginosa pneumonia in intensive care unit patients. Intensive Care Med 2013; 39:682.</a></li><li><a class="nounderline abstract_t">Murphy TF. Pseudomonas aeruginosa in adults with chronic obstructive pulmonary disease. Curr Opin Pulm Med 2009; 15:138.</a></li><li><a class="nounderline abstract_t">Miravitlles M, Espinosa C, Fernández-Laso E, et al. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Study Group of Bacterial Infection in COPD. Chest 1999; 116:40.</a></li><li><a class="nounderline abstract_t">Eller J, Ede A, Schaberg T, et al. Infective exacerbations of chronic bronchitis: relation between bacteriologic etiology and lung function. Chest 1998; 113:1542.</a></li><li><a class="nounderline abstract_t">Lode H, Allewelt M, Balk S, et al. A prediction model for bacterial etiology in acute exacerbations of COPD. Infection 2007; 35:143.</a></li></ol></div><div id="topicVersionRevision">Topic 3133 Version 27.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17564985" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Microbiology of ventilator-associated pneumonia compared with that of hospital-acquired pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12503708" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Nosocomial tracheobronchitis in mechanically ventilated patients: incidence, aetiology and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1864118" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Incidence, etiology, and outcome of nosocomial pneumonia in mechanically ventilated patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10432077" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Trends in nosocomial pneumonia in surgical patients as we approach the 21st century: a prospective analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12493178" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Respiratory tract pathogens isolated from patients hospitalized with suspected pneumonia in Latin America: frequency of occurrence and antimicrobial susceptibility profile: results from the SENTRY Antimicrobial Surveillance Program (1997-2000).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24146002" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Risk factors for Pseudomonas aeruginosa pneumonia in the early twenty-first century.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12588273" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17503016" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Pseudomonas aeruginosa carriage, colonization, and infection in ICU patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15243686" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Patterns of colonization by Pseudomonas aeruginosa in intubated patients: a 3-year prospective study of 1,607 isolates using pulsed-field gel electrophoresis with implications for prevention of ventilator-associated pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11235039" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Disseminated Pseudomonas aeruginosa and necrotizing pneumonia with complete recovery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21741117" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Identifying new risk factors for Pseudomonas aeruginosa pneumonia in intensive care units: experience of the French national surveillance, REA-RAISIN.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29976651" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Burden and risk factors for Pseudomonas aeruginosa community-acquired pneumonia: a multinational point prevalence study of hospitalised patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1469184" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Fulminant primary Pseudomonas aeruginosa pneumonia and septicaemia in previously well adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37317086" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : A Fatal Case of Pseudomonas aeruginosa Community-Acquired Pneumonia in an Immunocompetent Patient: Clinical and Molecular Characterization and Literature Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17278083" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12196083" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Community-acquired pneumonia due to gram-negative bacteria and pseudomonas aeruginosa: incidence, risk, and prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17635376" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14981752" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Pneumonia in HIV-infected patients in the HAART era: incidence, risk, and impact of the pneumococcal vaccination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18463787" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Bacterial community acquired pneumonia in HIV-infected inpatients in the highly active antiretroviral therapy era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32545992" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Risk Factor Evaluation for Methicillin-Resistant Staphylococcus aureus and Pseudomonas aeruginosa in Community-Acquired Pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21358441" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Community-acquired pneumonia in patients with liver cirrhosis: clinical features, outcomes, and usefulness of severity scores.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16510452" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Implications of COPD in patients admitted to the intensive care unit by community-acquired pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19679601" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Community-acquired pneumonia through Enterobacteriaceae and Pseudomonas aeruginosa: Diagnosis, incidence and predictors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12081224" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Person-to-person transmission of Pseudomonas pneumonia in the community: documentation by pulsed-field electrophoresis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12539092" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Hot tub-associated necrotizing pneumonia due to Pseudomonas aeruginosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12529461" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Pseudomonas aeruginosa and Serratia marcescens contamination associated with a manufacturing defect in bronchoscopes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12529462" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : An outbreak of Pseudomonas aeruginosa infections associated with flexible bronchoscopes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12392900" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Pseudomonas aeruginosa outbreak in a haematology-oncology unit associated with contaminated surface cleaning equipment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21467058" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Pneumonia due to Pseudomonas aeruginosa: part I: epidemiology, clinical diagnosis, and source.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23989176" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Assessment of severity of ICU-acquired pneumonia and association with etiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11828213" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Spectrum of CT findings in nosocomial Pseudomonas aeruginosa pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7818814" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Community-acquired Pseudomonas aeruginosa pneumonia in patients with HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14562290" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Pseudomonas pneumonia in infants: an autopsy study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24312174" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Is the improvement of CF patients, hospitalized for pulmonary exacerbation, correlated to a decrease in bacterial load?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15699079" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29789189" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Antimicrobial Susceptibility of Enterobacteriaceae and Pseudomonas aeruginosa Isolates from United States Medical Centers Stratified by Infection Type: Results from the International Network for Optimal Resistance Monitoring (INFORM) Surveillance Program, 2015-2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31563344" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30036695" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Evaluation of ceftazidime/avibactam for serious infections due to multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32548207" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Cefiderocol for Extensively Drug-Resistant Gram-Negative Bacterial Infections: Real-world Experience From a Case Series and Review of the Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28329350" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Multicenter Evaluation of Ceftolozane/Tazobactam for Serious Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30488041" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: A Multicenter Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30415002" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Ceftolozane/tazobactam for the treatment of serious Pseudomonas aeruginosa infections: a multicentre nationwide clinical experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34278551" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Systematic Literature Review of Real-world Evidence of Ceftolozane/Tazobactam for the Treatment of Respiratory Infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31890725" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Real-World Experience With Ceftazidime-Avibactam for Multidrug-Resistant Gram-Negative Bacterial Infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33106864" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrumβ-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33434676" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Evaluating the emergence of nonsusceptibility among Pseudomonas aeruginosa respiratory isolates from a phase-3 clinical trial for treatment of nosocomial pneumonia (ASPECT-NP).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32996064" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Healthcare Resource Utilization of Ceftolozane/Tazobactam Versus Meropenem for Ventilated Nosocomial Pneumonia from the Randomized, Controlled, Double-Blind ASPECT-NP Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31545346" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Ceftolozane/Tazobactam vs Polymyxin or Aminoglycoside-based Regimens for the Treatment of Drug-resistant Pseudomonas aeruginosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35292686" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Ceftolozane/tazobactam versus colistin in the treatment of ventilator-associated pneumonia due to extensively drug-resistant Pseudomonas aeruginosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35121161" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Ceftolozane-tazobactam vs. colistin for the treatment of infections due to multidrug-resistant Pseudomonas aeruginosa: a multicentre cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36610837" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Ceftolozane/tazobactam for the treatment of Pseudomonas aeruginosa infections: A multicenter case series analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36048335" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Impact of Ceftolozane-Tazobactam vs. Best Alternative Therapy on Clinical Outcomes in Patients with Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Lower Respiratory Tract Infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37180591" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : A Real-world Multicenter Outpatient Experience of Ceftolozane/Tazobactam.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29254862" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34379310" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Ceftazidime-Avibactam for the Treatment of Serious Gram-Negative Infections with Limited Treatment Options: A Systematic Literature Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37727274" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Ceftazidime-Avibactam for Carbapenem-Resistant Gram-Negative Bacteria Infections: A Real-World Experience in the ICU.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37890733" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Clinical efficacy of ceftazidime/avibactam combination therapy for severe hospital-acquired pulmonary infections caused by carbapenem-resistant and difficult-to-treat Pseudomonas aeruginosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34990760" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Effectiveness of ceftazidime-avibactam for the treatment of infections due to Pseudomonas aeruginosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37404159" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Ceftolozane-Tazobactam Versus Ceftazidime-Avibactam for the Treatment of Infections Caused by Multidrug-Resistant Pseudomonas aeruginosa: a Multicenter Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34120547" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : An overview of cilastatin + imipenem + relebactam as a therapeutic option for hospital-acquired and ventilator-associated bacterial pneumonia: evidence to date.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32785589" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34901302" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Early Multicenter Experience With Imipenem-Cilastatin-Relebactam for Multidrug-Resistant Gram-Negative Infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35136967" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Evolution of Imipenem-Relebactam Resistance Following Treatment of Multidrug-Resistant Pseudomonas aeruginosa Pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37463564" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33058798" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37062445" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Real-life use of cefiderocol for salvage therapy of severe infections due to carbapenem-resistant Gram-negative bacteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36943617" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Real-Life Data on the Effectiveness and Safety of Cefiderocol in Severely Infected Patients: A Case Series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37807834" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Cefiderocol use for the treatment of infections by carbapenem-resistant Gram-negative bacteria: an Italian multicentre real-life experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37795425" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : In vitro activity of cefiderocol against Pseudomonas aeruginosa demonstrating evolved resistance to novelβ-lactam/β-lactamase inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37846592" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Antibiotic therapy for nonfermenting Gram-negative bacilli infections: future perspectives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33431413" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Activity of Cefepime in Combination with the Novelβ-Lactamase Inhibitor Taniborbactam (VNRX-5133) against Extended-Spectrum-β-Lactamase-Producing Isolates in In Vitro Checkerboard Assays.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35007130" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : In Vitro Activity of Cefepime-Taniborbactam against Carbapenemase-Producing Enterobacterales and Pseudomonas aeruginosa Isolates Recovered in Spain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31298277" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Activity of cefepime/zidebactam (WCK 5222) against Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter baumannii endemic to New York City medical centres.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33332545" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : An update on cefepime and its future role in combination with novelβ-lactamase inhibitors for MDR Enterobacterales and Pseudomonas aeruginosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28665414" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : ETX2514 is a broad-spectrumβ-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36640133" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : In vivo pharmacokinetic/pharmacodynamic evaluation of cefepime/taniborbactam combination against cefepime-non-susceptible Enterobacterales and Pseudomonas aeruginosa in a murine pneumonia model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31235557" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : In Vivo Efficacy of WCK 5222 (Cefepime-Zidebactam) against Multidrug-Resistant Pseudomonas aeruginosa in the Neutropenic Murine Thigh Infection Model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29686157" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Antimicrobial Activity of Murepavadin Tested against Clinical Isolates of Pseudomonas aeruginosa from the United States, Europe, and China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29686157" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Antimicrobial Activity of Murepavadin Tested against Clinical Isolates of Pseudomonas aeruginosa from the United States, Europe, and China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29686157" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Antimicrobial Activity of Murepavadin Tested against Clinical Isolates of Pseudomonas aeruginosa from the United States, Europe, and China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17581492" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Optimal management therapy for Pseudomonas aeruginosa ventilator-associated pneumonia: an observational, multicenter study comparing monotherapy with combination antibiotic therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37254209" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Association between combination antibiotic therapy as opposed as monotherapy and outcomes of ICU patients with Pseudomonas aeruginosa ventilator-associated pneumonia: an ancillary study of the iDIAPASON trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26301604" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Short-course versus prolonged-course antibiotic therapy for hospital-acquired pneumonia in critically ill adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14625336" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35552788" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Comparison of 8 versus 15 days of antibiotic therapy for Pseudomonas aeruginosa ventilator-associated pneumonia in adults: a randomized, controlled, open-label trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36130230" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Less Is More? Antibiotic Treatment Duration in Pseudomonas aeruginosa Ventilator-Associated Pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36196675" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Less Is More: A 7-Day Course of Antibiotics Is the Evidence-Based Treatment for Pseudomonas aeruginosa Ventilator-Associated Pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20876621" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Randomized controlled trial of nebulized colistimethate sodium as adjunctive therapy of ventilator-associated pneumonia caused by Gram-negative bacteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27890714" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : A randomized trial of the amikacin fosfomycin inhalation system for the adjunctive therapy of Gram-negative ventilator-associated pneumonia: IASIS Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31866328" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Inhaled amikacin adjunctive to intravenous standard-of-care antibiotics in mechanically ventilated patients with Gram-negative pneumonia (INHALE): a double-blind, randomised, placebo-controlled, phase 3, superiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28412382" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Use of nebulized antimicrobials for the treatment of respiratory infections in invasively mechanically ventilated adults: a position paper from the European Society of Clinical Microbiology and Infectious Diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17350201" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Salvage treatment of pneumonia and initial treatment of tracheobronchitis caused by multidrug-resistant Gram-negative bacilli with inhaled polymyxin B.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16080101" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Nebulized colistin in the treatment of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10903263" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Treatment of nosocomial pneumonia and tracheobronchitis caused by multidrug-resistant Pseudomonas aeruginosa with aerosolized colistin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23989805" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Effect of aerosolized colistin as adjunctive treatment on the outcomes of microbiologically documented ventilator-associated pneumonia caused by colistin-only susceptible gram-negative bacteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23989805" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Effect of aerosolized colistin as adjunctive treatment on the outcomes of microbiologically documented ventilator-associated pneumonia caused by colistin-only susceptible gram-negative bacteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31437402" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Bacteriophage Therapy of Ventilator-associated Pneumonia and Empyema Caused by Pseudomonas aeruginosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31102236" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Successful adjunctive use of bacteriophage therapy for treatment of multidrug-resistant Pseudomonas aeruginosa infection in a cystic fibrosis patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36082999" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Development of Host Immune Response to Bacteriophage in a Lung Transplant Recipient on Adjunctive Phage Therapy for a Multidrug-Resistant Pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37508185" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Bacteriophage-Antibiotic Combination Therapy against Pseudomonas aeruginosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31207123" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Early clinical experience of bacteriophage therapy in 3 lung transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35444073" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Bacteriophage therapy for empyema caused by carbapenem-resistant Pseudomonas aeruginosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10491409" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Pathogenesis of septic shock in Pseudomonas aeruginosa pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10918093" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : [Risk factors and prognosis of nosocomial pneumonia due to gram-negative bacteria in a general hospital].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16460548" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Pandrug-resistant Pseudomonas aeruginosa among hospitalised patients: clinical features, risk-factors and outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23370828" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Clinical outcomes of Pseudomonas aeruginosa pneumonia in intensive care unit patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19532029" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Pseudomonas aeruginosa in adults with chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10424501" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Study Group of Bacterial Infection in COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9631791" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Infective exacerbations of chronic bronchitis: relation between bacteriologic etiology and lung function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17565454" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : A prediction model for bacterial etiology in acute exacerbations of COPD.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
